Ovarian hyperstimulation syndrome following ovulation induction with human menopausal gonadotropin.
Twenty-seven anovulatory women who had episode(s) of ovarian hyperstimulation during ovulation induction with hMG were studied. Twenty-nine of the total 89 treatment cycles were complicated by ovarian hyperstimulation. Twenty-four-hour urinary estrogen concentrations 3 days prior to hCG administration were significantly higher in the hyperstimulated (H) than in the nonhyperstimulated cycles (NH). Patients who had progesterone withdrawal bleeding (Group I) were more prone to be hyperstimulated in the first treatment cycle than patients who had no progesterone withdrawal bleeding (Group II). In all instances, the syndrome resolved spontaneously with time. The pregnancy rate of H was threefold NH. It is concluded that hyperstimulation in patients who had evidence of endogenous estrogen activity as demonstrated by progesterone withdrawal bleeding tend to occur in the first treatment cycle. Strict monitoring decreased the incidence of severe hyperstimulation. A minimal amount of hyperstimulation might be beneficial to improve the pregnancy rate.
D000328:Adult; D000858:Anovulation / Q000188:drug therapy; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D004967:Estrogens / Q000652:urine; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy; D008596:Menotropins / Q000009:adverse effects*; D010048:Ovarian Cysts / Q000139:chemically induced / Q000652:urine; D010053:Ovary / Q000187:drug effects*; D010062:Ovulation Induction; D011247:Pregnancy; D013577:Syndrome
D006063:Chorionic Gonadotropin; D004967:Estrogens; D008596:Menotropins